Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases, today announced that Dr David Stamler, Chief Executive Officer will present a company overview at the MST Access Australian Micro & Small Caps Conference on Thursday 17 June 2021 at ...
Highlights: Michael J. Fox Foundation grants Alterity $US495K for Parkinson’s disease research evaluation Strengthening profile at investment, scientific and clinical conferences Dr David Stamler appointed Chief Executive Officer Cash balance as at 31 March 2021 of A$32.8M Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) releases its Appendix 4C Quarterly Cash Flow ...
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) today announced an oral presentation of expanded animal data to support the commercialisation of its lead compound ATH434 in clinical development for the treatment of Parkinsonian disorders, at the American Academy of Neurology (AAN) virtual annual meeting. The AAN conference, held this week, is the ...
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) CEO Dr David Stamler is presenting to US investors this week as part of the HC Wainwright Global Life Science Conference. The conference held virtually, attracts specialist life science and healthcare investors and features leading companies from around the world. Dr Stamler’s presentation is appended ...
Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), will present at the upcoming 7th International Congress of Multiple System Atrophy (MSA2021), to be held in a virtual format from February 26-27, 2021. The event is a world leading conference on Multiple System Atrophy (MSA), a rapidly progressive and debilitating neurodegenerative disease without ...
Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), today advises it will release its financial results for the six-month period ending 31 December 2020 (H1 FY2021), on Thursday 25th February 2021. Investors are invited to join a live webcast and Q&A hosted by CEO Dr David Stamler and Chairman Geoffrey Kempler on ...
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) has today announced the award of a grant from The Michael J. Fox Foundation for Parkinson’s Research to determine optimal dosing of its lead drug candidate ATH434 for Parkinson’s disease (PD) based on imaging of brain iron. The funding for US$495,000 will be used to ...
Highlights: Dr David Stamler appointed CEO; Geoffrey Kempler continues as Non-Executive Chairman New commercial opportunity for PBT2 with UniQuest to reverse bacterial resistance to antibiotics US patent for next generation of compounds to treat neurodegenerative disease Phase 2 clinical program underway with commencement of enrollment in BioMUSE natural history study in US for patients with MSA $35M Placement to ...
New hope in global fight against antibiotic resistant superbugs
Receive news from Alterity Therapeutics
